Key result
Ambulatory percutaneous coronary angioplasty was safe in selected low-risk patients, with 0% major adverse cardiac events and 98.6% of patients reporting no abnormalities.
Why the study?
Growing PCI demand strains hospital beds, waiting times, costs, and personnel, prompting evaluation of the short-term safety of ambulatory PCI in carefully selected patients in a middle-income country.
Cohort (n=70)
No
Ambulatory percutaneous coronary intervention with same-day discharge is safe and feasible for carefully selected low-risk patients in a middle-income country setting, with no major adverse cardiac events observed.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for same-day discharge after low-risk ambulatory PCI; randomized trials needed before clinical adoption.
Background: Percutaneous coronary intervention (PCI) stands as the most employed coronary revascularization technique today. By the year 2020, more than 965,000 PCI procedures were performed in the United States. However, the growing demand for this procedure poses several challenges. It leads to a substantial occupancy of hospital beds, extended waiting times, increased procedural costs, and a heightened demand for healthcare personnel, all of which contribute to a reduction in the quality of care for patients with medical emergencies. Therefore, this research aims to assess the short-term safety of ambulatory percutaneous coronary intervention in carefully selected patients. Aims: The primary objective of this study is to determine the short-term safety of implementing ambulatory percutaneous coronary intervention in a middle-income country. Methods: This retrospective, single-center study was conducted in Santiago, Dominican Republic. The study population consisted of patients who underwent percutaneous coronary angioplasties between January and December 2022. Seventy patients who met the predefined inclusion criteria were included in the final sample. These patients were discharged within 24 hours of the procedure and subsequently contacted at 24-48 hours and 7-14 days post-procedure by the healthcare staff to monitor for any signs or symptoms of complications stemming from the intervention. Results: The study identified a few complications, with no abnormalities reported in 98.6% of patients. Hematoma emerged as the most observed alteration, and no major adverse cardiac events (MACE) were recorded. From the patient's perspective, individuals expressed satisfaction with the same-day discharge throughout the follow-up period, which extended to 7-14 days post-procedure. Conclusion: Ambulatory percutaneous coronary angioplasty was found to be a safe procedure, particularly in patients meeting specific low-case complexity criteria.
No takes yet. Share an insight, caveat, or question.
Cruz et al. (2023) conducted a cohort in Coronary artery disease requiring elective percutaneous coronary intervention (n=70). Ambulatory percutaneous coronary intervention (PCIa) was evaluated on Major adverse cardiac events (MACE) and procedural complications. Ambulatory percutaneous coronary angioplasty was safe in selected low-risk patients, with 0% major adverse cardiac events and 98.6% of patients reporting no abnormalities.
Synapse has enriched 10 related papers. Consider them for comparative context: